🇺🇸 FDA
Patent

US 9809824

CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods

granted A61PA61P37/04

Quick answer

US patent 9809824 (CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods) held by THE UNITED STATES OF AMERICA, represented by the Secretary, Department of Health and Human Services expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE UNITED STATES OF AMERICA, represented by the Secretary, Department of Health and Human Services
Grant date
Tue Nov 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61P, A61P37/04